Skip to content

Study · Randomized controlled trial · n = 68 · 2016

3 results

Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women.

Al-Saqi SH, Jonasson AF, Naessén T, Uvnäs-Moberg K

Post reproductive health15 Feb 2016Cited by 17 (Europe PMC)

PMID26883689 (opens in a new tab)DOI10.1177/2053369116629042 (opens in a new tab)PepBankPUB-26883689
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, topical oxytocin gel (vagitocin) increased the percentage of superficial vaginal cells between 0 and 2 weeks more than placebo gel.

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin gel increased healthy surface vaginal cells in the first 2 weeks more than placebo gel.

    Peptide
    Oxytocin
    Outcome
    IncreaseIncrease in percentage of superficial cells between 0 and 2 weeks
    Study

    n = 68

    Comparator
    Placebo gel
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    600 IU daily for 2 weeks, then 600 IU twice a week for 10 weeks · intravaginal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The increase in the percentage of superficial cells between 0 and 2 weeks was significantly greater after treatment with vagitocin in comparison with placebo (p = 0.04).
    2 context sentences
    Summary · context
    Sixty-eight postmenopausal women diagnosed with vaginal atrophy were randomized for this multicenter, double-blinded, placebo-controlled trial.
    Summary · context
    The dose was 600 IU daily for the first two weeks and thereafter 600 IU twice a week for 10 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, topical oxytocin gel (vagitocin) raised the maturation value between 0 and 12 weeks more than placebo gel.

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin gel improved the maturity of vaginal cells over 12 weeks more than placebo gel.

    Peptide
    Oxytocin
    Outcome
    IncreaseChange in vaginal maturation value between 0 and 12 weeks
    Study

    n = 68

    Comparator
    Placebo gel
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    600 IU daily for 2 weeks, then 600 IU twice a week for 10 weeks · intravaginal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The difference in the maturation value between 0 and 12 weeks was significantly higher in the vagitocin than in the placebo group (p = 0.01).
    2 context sentences
    Summary · context
    Sixty-eight postmenopausal women diagnosed with vaginal atrophy were randomized for this multicenter, double-blinded, placebo-controlled trial.
    Summary · context
    The dose was 600 IU daily for the first two weeks and thereafter 600 IU twice a week for 10 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, topical oxytocin gel (vagitocin) reduced histological atrophy scores more than placebo gel at 12 weeks.

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin gel lowered tissue signs of atrophy at 12 weeks more than placebo gel.

    Peptide
    Oxytocin
    Outcome
    DecreaseHistological atrophy score at 12 weeks
    Study

    n = 20

    Comparator
    Placebo gel
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    600 IU daily for 2 weeks, then 600 IU twice a week for 10 weeks · intravaginal · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The reduction in the scores of atrophy was according to the histological investigation significantly greater in the vagitocin group than in the placebo group at 12 weeks (p < 0.04).
    2 context sentences
    Summary · context
    Sixty-eight postmenopausal women diagnosed with vaginal atrophy were randomized for this multicenter, double-blinded, placebo-controlled trial.
    Summary · context
    The dose was 600 IU daily for the first two weeks and thereafter 600 IU twice a week for 10 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.